Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
maraviroc
- Development stage
- Approved
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Maraviroc is a small molecule chemokine receptor antagonist developed by Pfizer. It is used in combination with other antiretroviral medications to treat CCR5-tropic HIV-1 infection in adults and children weighing at least 2 kg. Maraviroc works as an entry inhibitor by selectively binding to the human chemokine receptor CCR5 on the surface of CD4 cells (T-cells), thereby preventing HIV-1 gp120 from interacting with CCR5 and blocking viral entry into host cells. This mechanism helps reduce viral load and slows immune system decline but does not cure HIV or AIDS[3][9][10].
- Brand names
- SelzentryCelsentri
- Other names
- maravirocum
02
Targets
CCR5 (C-C chemokine receptor type 5)
Beyond the preview
Go deeper on maraviroc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on maraviroc.